Combo Provides ‘Broad Benefit’ Across NHL Subtypes
The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progressi...
GSK and Vir Seek Emergency Use of COVID-19 Therapy in United States
(Reuters) – GSK and Vir Biotechnology have f...
Denosumab Now Dominant Therapy for Cancer-Associated Osteoporosis
Amid a substantial expansion of therapies in sever...
Newly Approved Drugs Offer New Hope in NMOSD
While they’re extraordinarily expensive, a t...
Dupilumab an Option When Other Targeted Agents Fail in Aspirin-Exacerbated Respiratory Disease
NEW YORK (Reuters Health) – Dupilumab, a mon...
Novel Agent Shows Promise Against Cat Allergy
One dose of the novel agent, REGN1908-1909 (Regene...
